口服抗凝药是轻度创伤性脑损伤进展的危险因素吗?一项聚焦直接口服抗凝药与维生素K拮抗剂的单中心经验
该单中心研究纳入因轻度创伤性脑损伤就诊且入院CT阳性的连续患者,比较口服抗凝治疗(维生素K拮抗剂或直接口服抗凝药)与创伤后颅内出血进展的关联。多变量分析显示,仅口服抗凝治疗与颅内出血进展风险增加显著相关(VKA HR 2.58,95%CI 1.411-4.703,p=.002;DOAC HR 1.9,95%CI 1.004-3.735,p=.0048)。作者认为需进一步研究以明确患者管理及DOAC相比VKA的安全性。
要点
- 轻度TBI且入院CT阳性的患者中,口服抗凝治疗与颅内出血进展风险增加显著相关。
- VKA的进展风险HR为2.58(95%CI 1.411-4.703,p=.002),DOAC为HR 1.9(95%CI 1.004-3.735,p=.0048)。
- 手术主要因孤立性硬膜下血肿(87.5%),13例(4.35%)在ICU死亡。
核心结论
- 在本系列中,抗凝与颅内进展显著增加相关,但这对当前临床实践意味着什么仍是未解问题;硬膜下血肿是与演变和手术相关的主要发现。
- 作者认为需要进一步研究以明确轻度TBI患者的管理及DOAC相比VKA的安全性特征。
研究设计与样本
- 单中心研究,连续纳入因轻度TBI为主诉就诊于急诊科且入院CT阳性的患者记录。
- 研究期间共4667例患者因轻度TBI接受CT扫描,其中439例(9.4%)发现颅内出血。
- 439例中299例(68.1%)被安排观察和控制性CT,其中46例(15.38%)接受抗凝治疗,23例(50%)使用VKA,23例(50%)使用DOAC。
- 采用Cox比例风险模型计算病因特异性风险比(HR)和95%置信区间(CI)。
主要发现
- 多变量分析中,仅口服抗凝治疗与颅内出血进展风险增加显著相关:VKA的HR为2.58(95%CI 1.411-4.703,p=.002),DOAC的HR为1.9(95%CI 1.004-3.735,p=.0048)。
- 手术原因中,孤立性硬膜下血肿占87.5%,硬膜下血肿合并脑实质出血占9.38%,仅脑实质出血占3.12%。
- 13例(4.35%)在重症监护室死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mild traumatic brain injury (TBI) in anticoagulated patients is a common challenge for emergency departments because of lack of appropriate epidemiological data and huge management variability for those under oral anticoagulation therapy. Given the discrepancies between guidelines, the aim of the present study was to quantify the association between oral anticoagulant therapy (either vitamin K antagonist (VKA) or direct oral anticoagulant (DOAC)) and the post-traumatic intracranial hemorrhage worsening compared to admission CT scan. METHODS: We included all consecutive records of patients admitted to our emergency department for mild TBI as chief complaint and with a positive admission CT scan. After statistical univariate comparison, cause-specific hazard ratio (HR) and 95% confidence interval (CI) were determined with the use of Cox proportional hazard model. RESULTS: In the study period, 4667 patients had a CT scan for mild TBI; 439 (9.4%) were found to have intracranial hemorrhage. Among these patients, 299 (68.1%) were prescribed observation and control CT: 46 (15.38%) were on anticoagulant therapy, 23 (50%) on VKA, and 23 (50%) on DOAC. In multivariate analysis, only oral anticoagulation therapy was significantly associated to an increased risk of intracranial hemorrhage progression (HR 2.58; 95% CI 1.411-4.703; p = .002 and HR 1.9; 95% CI 1.004-3.735; p = .0048 for VKA and DOAC, respectively). Surgery was due to isolated subdural hematoma in 87.5% of cases, to subdural hematoma associated with intraparenchymal hemorrhage in 9.38% and to intraparenchymal hemorrhage only in 3.12%; 13 cases (4.35%) deceased in intensive care unit. CONCLUSIONS: In our series, anticoagulation was associated to a significant increase in intracranial progression, leaving the question open as to what this implies in current clinical practice; subdural hematoma was the major finding associated to evolution and surgery. Against this background, further studies are needed to clarify patients' management and DOAC safety profile compared to VKA in mild TBI.
引用
- Della Pepa GM, Covino M, Menna G, et al. Are oral anticoagulants a risk factor for mild traumatic brain injury progression? A single-center experience focused on of direct oral anticoagulants and vitamin K antagonists. Acta Neurochir (Wien). 2021. PMID: 34850288. doi:10.1007/s00701-021-05066-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。